Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2014; 20(36): 12900-12907
Published online Sep 28, 2014. doi: 10.3748/wjg.v20.i36.12900
Published online Sep 28, 2014. doi: 10.3748/wjg.v20.i36.12900
Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?
Jee Suk Chang, Woong Sub Koom, Youngin Lee, Hong In Yoon, Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 120-752, South Korea
Hyung Sik Lee, Department of Radiation Oncology, Dong-A University Hospital, Busan 602-715, South Korea
Author contributions: Chang JS and Koom WS contributed equally to this work as first authors; Koom WS and Lee HS designed the research; Chang JS, Koom WS, Lee Y, Yoon HI and Lee HS performed the research; Chang JS, Koom WS, Lee Y, Yoon HI and Lee HS analyzed the data; Chang JS, Koom WS, Lee Y and Lee HS wrote the paper.
Correspondence to: Hyung Sik Lee, MD, Department of Radiation Oncology, Dong-A University Hospital, 1-3 Dongdaesindong, Seo-gu, Busan 602-715, South Korea. hyslee@dau.ac.kr
Telephone: +82-51-2405380 Fax: +82-51-2402135
Received: October 28, 2013
Revised: January 24, 2014
Accepted: April 5, 2014
Published online: September 28, 2014
Revised: January 24, 2014
Accepted: April 5, 2014
Published online: September 28, 2014
Core Tip
Core tip: The survival benefits of postoperative chemoradiotherapy (CRT) in gastric cancer with D0/1-dissection have been established in Western countries. However, in Eastern areas, where D2-dissection is the standard surgical procedure, most surgeons are skeptical about the benefit of CRT in D2-dissected patients, and CRT has not been examined in this setting in clinical trials. Here we aimed to provide a review of recent research and to suggest future directions regarding adjuvant CRT after D2-dissection.